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Abstract
In Norway, Pap smears with atypical squamous cells of uncertain significance
(ASCUS) and low-grade squamous intraepithelial lesions (LSIL) are triaged after
6 months. The aim of the study was to evaluate effects of implementing human
papillomavirus (HPV) test (2005) in delayed triage of ASCUS and LSIL in a
cohort of women from Western Norway. After a survey of 119,469 cervical Pap
smears during 2005–2007, a total of 1055 women with an index ASCUS or LSIL
were included in the study and followed up for 3–6 years with respect to progres-
sion into cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Overall sen-
sitivity for detection of CIN2+ with HPV testing and cytology was 96% and 72%,
respectively. The sensitivity for detection of CIN2+ was not affected by age, but
the specificity of the HPV test increased with age. Thus, for the age groups
<34 years, 34–50 years, and >50 years, the specificity of a positive HPV test to
detect CIN2+ was 47%, 71%, and 82%, respectively. Positive predictive values for
CIN2+ in women with positive cytology, positive HPV test, negative cytology,
negative HPV test, or negative HPV and cytology tests were 52%, 41%, 8%, 1.5%,
and 0.4%, respectively. HPV testing resulted in a net 22% increased detection of
CIN2+. Fifty-six percent of CIN2+ was detected at an earlier time point with HPV
testing in triage. Implementation of HPV testing in delayed triage of ASCUS and
LSIL improved the stratification of CIN2+ risk and increased CIN2+ detection
and at an earlier time point than with triage by cytology alone.
Introduction
Uterine cervical cancer is the second most common cancer
among women worldwide [1]. Squamous cell carcinomas
account for about 75–80% of the new cancer cases [2].
They develop through a multistep sequence of events from
low- through high-grade cellular lesions and then into
cancer [3, 4]. The cause of the disease is closely associated
with genital high-risk human papillomavirus (hrHPV)
infection [5–7], normally starting in the transitional zone
between the squamous and the columnar epithelium [8].
Most of the hrHPV infections regress spontaneously,
whereas some progress to high-grade lesions and eventually
into cancer [9]. It is generally assumed that it will take
more than 10 years from infection until development of
cancer [10]. Most developed countries have established
nationwide screening programs to detect and treat high-
grade cellular lesions and to monitor atypical squamous
cells of uncertain significance (ASCUS) and low-grade
squamous intraepithelial lesions (LSIL). These programs
are mainly based on cytology as the primary screening
method. The approach has proven useful in the sense that
the incidence rates of cervical cancer have decreased [11–
13] despite an increasing prevalence of genital hrHPV
infections in Western countries [14].
A hrHPV infection can be detected through HPV test-
ing. This method is more sensitive, but less specific than
cytology to detect clinical relevant infections [15, 16].
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Due to the higher sensitivity, some countries have in part
implemented HPV testing in primary screening [17].
Recent randomized trials have shown a higher detection
of CIN2 or worse (CIN2+) using HPV testing in primary
screening as compared to cytology [18–22]. Studies also
indicate that HPV-negative women can be referred to
routine screening with longer screening intervals [23, 24].
In 1995, an organized screening program for cervical
cancer was introduced in Norway. Women with an index
ASCUS or LSIL Pap smear were triaged with a control
smear after 6 months. In 2005, HPV testing was intro-
duced in the triage of ASCUS and LSIL within the
program.
In this study, we report on women with an index sam-
ple of ASCUS or LSIL and monitoring with cytology and
HPV testing in delayed triage. A major aim of this study
was to evaluate if HPV testing would recover more
CIN2+ than cytology alone and enable a more differenti-




In Norway, cervical screening is organized as a triennial
screening to all women, aged 25–69 years, and with a
written reminding letter to all non-attending women.
A total of 119,469 smears were screened during a 3-
year period from 2005 to 2007, and patients with ASCUS
or LSIL were identified. Among these, 1055 patients were
enrolled in the study. The patients were followed up over
the next 3–6 years with respect to progression into
CIN2+ based on diagnostic cervical biopsies and/or cervi-
cal resected cones. The more severe lesion was recorded.
All samples were examined at Haukeland University Hos-
pital, which is a regional hospital of Western Norway.
Definitions
Positive cytology means a Pap smear [25] showing ASCUS
or worse (ASCUS+). Negative cytology means a normal or
reactive smear without suspicion of ASCUS+. Index sam-
ple refers to the initial Pap smear that showed ASCUS or
LSIL and led to enrollment in the study. The first follow-
up test refers to the first control test performed after the
index sample.
Inclusion criteria
All women encountered with ASCUS or LSIL during the
period 2005–2007 were evaluated for enrollment. Women
with a positive cytology or positive HPV test during the
previous 2 years were excluded. These women were not
considered to have a de novo cytologically encountered
cervical lesion. Lack of such information did, however,
not exclude women from being enrolled in the study, as
many of these women had never attended a screening
program previously. Furthermore, the HPV test should be
sampled together with the first follow-up smear or less
than 1 month before or after the smear was taken.
Patient material
A total of 2172 women with ASCUS or LSIL were identi-
fied. Women with (1) prior abnormal smear(s) and/or
positive HPV tests, (2) lack of follow-up information,
and incomplete HPV follow-up of ASCUS/LSIL were
omitted from the study (Fig. 1). The study has been
approved by the Regional Committee for Ethics in
Research (2013/805).
HPV DNA test
A separate brush sample for HPV testing was normally
taken in parallel with the Pap smear. The HPV samples
were stored at 4°C until further processing. The HPV
DNA test (digene HC2 HPV DNA test, QIAGEN, Hom-
brechtikon, Switzerland) identifies the presence of hrHPV
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
without notifying the presence of any single hrHPV sub-
type. The HPV test results were normally not available to
the cytotechnicians screening the smears, but available to
the pathologist who finally signed out the smears.
Effect of HPV test in delayed triage versus
cytology alone
In delayed triage of ASCUS and LSIL, standard follow-up
is with repeat cytology after 6 months. Since 2005, HPV
testing has been used together with cytology for women
aged 25–69 years. In this study, the effect of HPV testing
on recovery of CIN2+ as well as the time interval from
index ASCUS/LSIL until detection of CIN2+ was evalu-
ated. For this purpose, all cytology and surgical pathology
reports of all the women included in the study were
examined.
A major difference in the triage algorithm with HPV
testing (and cytology) versus cytology alone is that HPV-
positive women will be referred for immediate colposcopy
if cytology is positive. HPV-positive women with negative
cytology are also followed up with new cytology smears
and/or colposcopy until the HPV test is negative (regres-
sion of disease) or has progressed to CIN2+. All HPV-
negative women are referred back to routine screening. In
the triage modality with cytology alone, an index ASCUS
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sample is referred back to routine screening if the follow-
up cytology is normal (negative). For index LSIL, two
ensuing cytology smears must be normal before the
woman is referred back to routine screening. A woman
will be referred for colposcopy if two ensuing repeat con-
trol tests show persistent equivocal or low-grade lesions.
In both screening modalities, immediate colposcopy will
follow if cytology shows high-grade lesion or suspicion of
its presence.
An evaluation of the cervical test records in relation to
the clinical management algorithms was done by three
cytopathologists (E. B. B., H. K. H., O. K. V.). A
complete outline of the management guidelines of
ASCUS/LSIL is available at The Cancer Registry of Norway
(www.kreftregisteret.no).
Statistical analysis
Assessment of sensitivity, specificity, and positive predic-
tive values (PPVs) for detection of CIN2+ in cytology
and with HPV testing refer to the first follow-up cytol-
ogy and HPV test taken after index ASCUS/LSIL. The
cytology test was considered correctly positive if
ASCUS+ identified a woman with CIN2+ or one who
developed CIN2+ during follow-up. This definition of
true positivity in cytology has also been used by others
[26]. Similarly, the HPV test was considered correctly
positive if the woman had CIN2+ or developed CIN2+
during follow-up.
Cumulative incidence rates were calculated using the
method described by Kaplan and Meier [27]. Pearson’s
chi-squared test was used to evaluate the associations
between categorical variables for results obtained in cytol-
ogy versus HPV testing.
Results
General observations
Sixty-eight percent of the women in the study group
(Fig. 1) had their first follow-up (control) test 4–
12 months after the index sample, 19% earlier than
4 months, and 12% later than 12 months. At the first
control of ASCUS/LSIL, 515 women had negative cytol-
ogy and negative HPV test, 260 positive cytology and
positive HPV test, 246 negative cytology and positive
HPV test, and 34 had positive cytology and negative HPV
test. The HPV test was positive in 37% of women with
index ASCUS and in 70% of women with index LSIL,
respectively (Table 1).
Age groups in relation to ASCUS, LSIL, HPV,
and CIN2+ detection
Most women with LSIL were younger than 34 years,
whereas most women with ASCUS were older than
34 years (Table 1). A skewed age distribution of ASCUS
and LSIL was similarly reflected in a high prevalence of
HPV positivity in young (<34 years) as compared to
elderly women (>50 years). Thus, for the age groups
<34 years, 34–50 years, and >50 years, the ASCUS/LSIL
ratio was 1.0, 2.6, and 6.2. HPV positivity in the LSIL
group was 73%, 71%, and 57%, and HPV positivity in
the ASCUS group was 57%, 32%, and 19%, respectively.
The significance of cytology and HPV testing for detec-
tion of women with CIN2+ was then evaluated in delayed
triage. Among 1055 women with index ASCUS or LSIL,
214 CIN2+ were recovered during the observation period
of 3–6 years (Table 2). The sensitivity for detection of
Figure 1. Flowchart of study inclusion.
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CIN2+ with HPV testing was 96% and for cytology 72%.
The sensitivity for detection of CIN2 in the age groups
<34 years, 34–50 years, and >50 years was 70%, 73%, and
75% in cytology and 97%, 97%, and 83% with HPV testing,
respectively. The specificity for detection of CIN2+ in the
age groups <34 years, 34–50 years, and >50 years was 81%,
84%, and 85% in cytology and 47%, 71%, and 82% with
HPV testing, respectively. Thus, the specificity of cytology
to identify CIN2+ was unaffected by age, whereas the speci-
ficity of HPV test to identify CIN2+ was affected by age.
Ninety-four percent of all CIN2+ were observed in the age
groups below <50 years and more than half (51%) of all
CIN2+ were recovered in women <34 years (Table 2).
Risk stratification of women with HPV test
in triage of ASCUS/LSIL
Cumulative incidence rates of CIN2+ in women with
positive cytology, positive HPV test, negative cytology, or
negative HPV test were determined. The risk of CIN2+
was high during the first 2 years after index ASCUS or
LSIL, and then no further increase was seen (Fig. 2).
A negative HPV test was superior to a negative cytology
test to predict a low risk for CIN2+.
The risks of CIN2+ in relation to possible test results
were further calculated and reported as PPVs for CIN2+
(Fig. 3). PPVs for CIN2+ given a positive HPV test were
high in this study, indicating a strong selection of clinical
relevant HPV-positive lesions by the used modality for
triaging of ASCUS or LSIL. The risks of CIN2+ in the
ASCUS and LSIL group of women were closely similar if
the HPV tests were positive (Fig. 3). The results of the
HPV testing also markedly affected the risk of CIN2+ in
cytology. Thus, the risk (PPV) of CIN2+ in women with
negative cytology was 6.7% as compared to 0.4% if the
HPV test was negative (Fig. 3).
Effect of HPV testing on CIN2+ detection
A delayed triage algorithm with cytology and HPV testing
versus cytology alone was evaluated for recovery of
CIN2+ in women with index ASCUS or LSIL. A net 22%
increased CIN2+ detection (P = 0.009) was observed by
HPV testing in triage as compared to cytology alone
(Fig. 4, upper panel). This effect was most prominent in
women with index ASCUS. In this group, HPV testing
led to a net 39% increase in CIN2+ recovery as compared
to cytology alone (P = 0.004). In index LSIL women,
HPV testing led to only a moderate 8.5% increased detec-
tion of CIN II (P = 0.4).
Then, the two various triage modalities with cytology
and HPV test combined versus cytology alone were evalu-
ated with respect to the time delay from index ASCUS/
LSIL until detection of CIN2+. For that purpose, all the
cytology and surgical pathology reports of women with
CIN2+ were reviewed (see Methods section). In the triage
modality with cytology and HPV testing CIN2+ was
detected at an earlier time point than in the triage modality
with cytology alone (Fig. 4, lower panel). Thus, with index
Table 1. Number (No) of women in various age groups with respect
to (1) ASCUS and LSIL (index smear [cytology]), (2) test results at the
first control, (3) HPV test results at first control versus index smear,
and (4) the whole study population (all women).
Age groups










ASCUS 217 (31) 320 (46) 161 (23) 698
LSIL 209 (59) 122 (34) 26 (7) 357
Test results 1st control
Cyt. pos. 135 (46) 124 (42) 35 (12) 294
Cyt. neg. 289 (38) 320 (42) 152 (20) 761
HPV pos. 275 (54) 190 (38) 41 (8) 506
HPV neg. 151 (28) 252 (46) 146 (27) 549
HPV test 1st control/index cytology
HPV pos./ASCUS
index
123 (48) 103 (40) 30 (12) 256
HPV neg./ASCUS
index
94 (21) 217 (49) 131 (30) 442
HPV pos./LSIL index 152 (61) 87 (35) 11 (4) 250
HPV neg./LSIL index 57 (53) 35 (33) 15 (14) 107
All tests (all women) 426 (40) 442 (42) 187 (18) 1055
HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial
lesions.
Number of women given in bold, fraction (%) of women given in italic.
Table 2. Number (No) of women in various age groups developing
CIN2+ during 3–6 years of follow-up after index ASCUS or LSIL in
relation to the whole study population (All tests, lower lane) and in
relation to observed findings in cytology and/or HPV test at their first
follow-up control.
Age groups









Test results 1st control
HPV pos. 106 (51) 90 (44) 10 (5) 206
Cyt. pos. 76 (50) 68 (44) 9 (6) 153
HPV pos./Cyt. pos. 74 (50) 66 (45) 7 (5) 147
Cyt. neg 33 (54) 25 (41) 3 (5) 61
HPV neg. 3 (38) 3 (38) 2 (25) 8
HPV neg/Cyt. pos 2 (33) 2 (33) 2 (33) 6
HPV neg. Cyt. neg. 1 (50) 1 (50) 0 (0) 2
All tests (all woman) 109 (51) 93 (44) 12 (6) 214
HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial
lesions.
Number of women given in bold, fraction (%) of women given in italic.
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ASCUS or LSIL Pap smear CIN2+ was detected at an ear-
lier time point in 56% and 53% of the cases, respectively.
Discussion
In this study, we addressed the effects of implementing
HPV testing in delayed triage of ASCUS and LSIL in the
organized population-based cervical cancer screening pro-
gram in Norway. It was noted that the significance of
ASCUS in terms of the risk for CIN2+ was similar to
LSIL when corrected for HPV status. High PPVs of
HPV-positive women for CIN2+ suggested that the clini-
cally relevant HPV infections were identified by the
delayed triage algorithm. HPV testing not only led to an
increased CIN2+ detection but also to a shorter time
interval until CIN2+ was detected.
Apart from some women who were excluded due to a
previous history of ASCUS+ or lack of clinical follow-up
information, 689 women (39%) with ASCUS or LSIL at
baseline did not have a HPV test at their first follow-up
smear (Fig. 1). In the study (HPV) group, CIN2+ was
recovered in 20% of the women, whereas in the group of
Figure 2. Cumulative incidence rates for CIN2+ based on test (HPV and cytology) results at the first follow-up control in women with an index
ASCUS or LSIL (Kaplan–Meyer plots). HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesions.
Figure 3. Positive predictive values for CIN2+ based on test (HPV and cytology) results at the first follow-up control in women with an index
ASCUS or LSIL. HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesions.
186 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
HPV Testing in Triage of ASCUS and LSIL E. B. Budal et al.
689 non-HPV tested women 19%, CIN2+ was detected
(see Fig. 1). This indicated that there was no major differ-
ence in CIN2+ prevalence between these two groups.
In the ALT’s study, triage of ASCUS with HPV test was
clinically useful, but of limited value in triage of LSIL as
most (82.9%) of these women were reported to be HPV
positive [28]. In this study, using the modality of delayed
triage, HPV test was positive in 37% of women with
ASCUS and in 70% of women with LSIL (Table 1). This
indicated a more clinically relevant role of HPV testing in
delayed triage of LSIL. Moreover, in women >50 years,
86% of ASCUS/LSIL smears were of the ASCUS type and
only 19% of the latter were positive for HPV. The same
age-dependent effect was observed in the ALT’s study and
also more recently by Gyllensten and coworkers [29].
The cumulative incidence rates of CIN2+ in the HPV-
positive women were high in this study (Fig. 2) as com-
pared to studies where HPV testing was done at baseline
(reflex HPV testing) [30–32]. A higher cumulative inci-
dence rate of CIN2+ has been reported in women with
persistent HPV infection [33, 34]. In a recent study, two
thirds of all HPV infections underwent spontaneous
regression within 1 year [35]. It has been reported that a
less aggressive approach of HPV testing at baseline allow
more HPV infections to undergo spontaneous regression
before being triaged [36]. The high PPVs for CIN2+ in
HPV-positive women in this study also indicated that
clinically relevant lesions were found using a strategy with
delayed HPV triage of ASCUS and LSIL.
HPV testing has for a long time been shown to have a
superior negative predictive value (NPV) for developing
CIN2+ at baseline [23, 37–39]. Similar results were also
observed in this study where baseline ASCUS and LSIL
smears were triaged 6–12 month later with cytology and
HPV testing (Fig. 3). Although few in number, women
with negative HPV test and positive cytology had a con-
siderably increased risk of CIN2+ (Fig. 3). This should
raise some concern as to rely too heavily on a single nega-
tive HPV test, if the cytology is positive.
In this study, an effect of cytology and HPV testing
versus cytology alone on detection of CIN2+ in triage of
ASCUS and LSIL was based on the evaluation of all cytol-
ogy and surgical pathology reports of each woman with
CIN2+ included in the study. This approach will only
give estimates for detection of CIN2+ with and without
HPV testing in triage of ASCUS and LSIL, and is related
to the assumption that women triaged with cytology
alone fully adopt the clinical management algorithm.
Also, the effect of implementing HPV testing in triage is
based on results at the first follow-up after index ASCUS
and LSIL. This means that the potential for a secondary
catch up of a previously missed CIN2+ in the first screen-
ing round with cytology or HPV test is not accounted for
by this approach.
We report an estimated net 22% increased recovery
of CIN2+ by the use of HPV testing versus cytology
alone (Fig. 4). More than half of the CIN2+ lesions
were detected at an earlier time point with HPV testing
HPV test and CIN2+ detection ASCUS (%) LSIL (%) Total (%)
More swift CIN2+ detection 56 53 55
Indifferent CIN2+ detection 44 47 45
Figure 4. Effect of cytology and HPV test versus cytology alone on detection of CIN2+ (upper panel) and on the time course for detection of
CIN2+ (lower panel) in triage of ASCUS and LSIL. HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesions.
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in triage as compared to cytology alone (Fig. 4, lower
panel). However, this could represent a caveat in the
sense that not only the numbers of CIN2+ lesions
detected but also their potential to regress and progress
into cancer are of importance. Thus, a more protracted
detection of CIN2+ might identify fewer high-grade
lesions, but of higher clinical relevance [21]. An
increased detection of CIN2+ has been registered after
implementation of HPV testing in triage of ASCUS/
LSIL in Norway [40]. Randomized controlled trial(s) on
the effect of HPV testing in triage of ASCUS/LSIL have
not been performed in Norway.
It was observed that in a screening modality based on
delayed triage of ASCUS/LSIL very few women with an
index ASCUS smear above 50 years of age were HPV-
positive, and for those the specificity of a positive HPV
test for CIN2+ approached the specificity of a positive
cytology test. Furthermore, HPV testing led to an
increased and more rapid detection of CIN2+ and to an
improved stratification of CIN2+ risk. Thus, positive
HPV tests showed high PPVs for CIN2+, indicating that
the clinical relevant lesions were identified in this screen-
ing algorithm. A particular low risk for CIN2+ was
observed in HPV test negative women indicating that a
more differentiated routine screening protocol could be
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